{"slideshow_credits": null, "snippet": "Competition and discounts are going a long way toward resolving the problem of expensive hepatitis C drugs.", "abstract": "Editorial warns that powerful drugs recently approved to treat Hepatitis C, disease which killed 20,000 Americans in 2013, might become too expensive for insurers to offer; cites drugs like Sovaldi, which can cost around $1000 per pill; criticizes state Medicaid programs' efforts to reduce costs by restricting availability, and encourages insurers to continue pressing for discounts.", "section_name": "Opinion", "print_page": "24", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "web_url": "http://www.nytimes.com/2015/09/02/opinion/costly-hepatitis-c-drugs-for-everyone.html", "lead_paragraph": "Competition and discounts are going a long way toward resolving the problem of expensive hepatitis C drugs.", "headline": {"print_headline": "Costly Hepatitis C Drugs for Everyone?", "main": "Costly Hepatitis C Drugs for Everyone?", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "55e6a36238f0d86bbc6506db", "word_count": "526", "multimedia": [{"height": 126, "url": "images/2015/09/02/opinion/02wed2/02wed2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/09/02/opinion/02wed2/02wed2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 746, "url": "images/2015/09/02/opinion/02wed2/02wed2-articleLarge.jpg", "legacy": {"xlarge": "images/2015/09/02/opinion/02wed2/02wed2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "746"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/09/02/opinion/02wed2/02wed2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/09/02/opinion/02wed2/02wed2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-09-02T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"name": "subject", "value": "Editorials", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Harvoni (Drug)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Sovaldi (Drug)", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Medicaid", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Gilead Sciences Inc", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Hepatitis", "is_major": "Y", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}